Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2431 Target Snapshot

RAC-beta serine/threonine-protein kinase · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
3,417Compounds
546Assays
4Approved Drugs
2,908.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

RAC-beta serine/threonine-protein kinase shows clinical signal disease relevance led by neoplasm. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P31751. Start with neoplasm, then reuse UniProt P31751 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with neoplasm, then reuse UniProt P31751 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
neoplasm

RAC-beta serine/threonine-protein kinase shows clinical signal disease relevance led by neoplasm. 1 linked drug remains visible in the same block.

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include BAY-1125976. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats RAC-beta serine/threonine-protein kinase as ChEMBL target CHEMBL2431, mapped to UniProt P31751. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
RAC-beta serine/threonine-protein kinase
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2431
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P31751
RAC-beta serine/threonine-protein kinase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether RAC-beta serine/threonine-protein kinase is the right protein anchor across sources, using UniProt P31751 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why neoplasm is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameRAC-beta serine/threonine-protein kinase
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP31751
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRAC-beta serine/threonine-protein kinase
UniProt AccessionP31751
Component TypeProtein
Sequence Length481 aa

RAC-beta serine/threonine-protein kinase

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as RAC-beta serine/threonine-protein kinase, mapped to UniProt P31751. Sequence length is 481 aa.

Mapped IDP31751
Review nameRAC-beta serine/threonine-protein kinase
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

RAC-beta serine/threonine-protein kinase shows clinical signal disease relevance led by neoplasm.

Clinical signal Phase I
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugBAY-1125976
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include BAY-1125976. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseneoplasm
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

4
Approved
7
Phase III
7
Phase II
6
Phase I
Assay Mix

Activity Type Distribution

IC501,699.0
KI815.0
EC5019.0
KD375.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL4440965 9.7 IC50 0.2 Preclinical
CHEMBL3701767 9.59 IC50 0.26 Preclinical
CHEMBL3701740 9.57 IC50 0.27 Preclinical
CHEMBL3701766 9.55 IC50 0.28 Preclinical
CHEMBL3701717 9.54 IC50 0.29 Preclinical
CHEMBL3701737 9.52 IC50 0.3 Preclinical
CHEMBL3701769 9.51 IC50 0.31 Preclinical
CHEMBL3701762 9.49 IC50 0.32 Preclinical
CHEMBL3701732 9.46 IC50 0.35 Preclinical
CHEMBL3701775 9.4 IC50 0.4 Preclinical
Distribution

pChEMBL Value Distribution

117
5.0
147
5.5
237
6.0
327
6.5
325
7.0
237
7.5
161
8.0
67
8.5
61
9.0
13
9.5
pChEMBL
Approved Drugs

Approved Drugs

CAPIVASERTIB
CHEMBL2325741
Approved 2023
Properties Compare Identifier
MIDOSTAURIN
CHEMBL608533
Approved 2017
Properties Compare Identifier
Assay Landscape

Assay Landscape

546
Total Assays
1,097
Tested Compounds
3
Assay Types
Binding — 538 assays, 1,097 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 410 630 6.9
cell-based format 78 419 7.3
assay format 49 43 7.2
subcellular format 1 5 6.3
Functional — 7 assays, 126 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 4 3 6.1
assay format 3 123 5.8
Toxicity — 1 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 1 8.6

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine